ReviewWorld journal of critical care medicine2023
Biomarkers in sepsis-looking for the Holy Grail or chasing a mirage!
Review in World journal of critical care medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Ruling In and Ruling Out Sepsis Using Likelihood Ratios of a Host Response Assay.Diagnostics (Basel, Switzerland) · 2026Article
- Role of Matrix Metalloproteinases and Tissue Inhibitors in Sepsis Pathogenesis.Medical sciences (Basel, Switzerland) · 2026Article
- Comparison of serial pancreatic stone protein, C-reactive protein and procalcitonin for the diagnosis of infection and sepsis in critically Ill patients: a multicentre prospective study.BMC anesthesiology · 2026Article
- Systemic Inflammatory Response Index (SIRI) Among Patients With Sepsis: A Retrospective Observational Study.Cureus · 2026Article
- Prognostic Nutritional Index (PNI) in Patients With Diabetes and Sepsis: A Cross-Sectional Study.Cureus · 2026Article
- C-reactive Protein-Albumin-Lymphocyte (CALLY) Index in Patients With Sepsis: An Observational Study.Cureus · 2026Article
- Procalcitonin-guided antibiotic therapy in adult sepsis: A biochemical perspective from a retrospective cohort study.Journal of medical biochemistry · 2026Article
- From sepsis biomarker discovery to regulatedFrontiers in medical technology · 2026Review
- Sepsis-induced cardiac dysfunction: mitochondria and energy metabolism.Intensive care medicine experimental · 2025Review
- Clinical and mechanistic relevance of high-dimensionality analysis of the paediatric sepsis immunome.Frontiers in immunology · 2025Article
- Hospital Acquired Sepsis, Disease Prevalence, and Recent Advances in Sepsis Mitigation.Pathogens (Basel, Switzerland) · 2024Review
- Antibiotic Stewardship in Surgical Departments.Antibiotics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is defined as a life-threatening organ dysfunction caused by the dysregulated host response to infection. It is a complex syndrome and is characterized by physiologic, pathologic and biochemical abnormalities in response to an infection. Diagnosis of sepsis is based on history, physical examination and other investigations (including biomarkers) which may help to increase the certainty of diagnosis. Biomarkers have been evaluated in the past for many diseases and have been evaluated for sepsis as well. Biomarkers may find a possible role in diagnosis, prognostication, therapeutic monitoring and anti-microbial stewardship in sepsis. Since the pathophysiology of sepsis is quite complex and is incompletely understood, a single biomarker that may be robust enough to provide all information has not been found as of yet. However, many biomarkers have been studied and some of them have applications at the bedside and guide clinical decision-making. We evaluated the PubMed database to search for sepsis biomarkers for diagnosis, prognosis and possible role in antibiotic escalation and de-escalation. Clinical trials, meta-analyses, systematic reviews and randomized controlled trials were included. Commonly studied biomarkers such as procalcitonin, Soluble urokinase-type plasminogen activator (Supar), presepsin, soluble triggering receptor expressed on myeloid cells 1, interleukin 6, C-reactive protein,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.